Drawing for BIOMARIN

USPTO serial 78738394

BIOMARIN

Reviewed by CopyMark Law Group

Reg. 3192347Status 800Renewal
Filing date
Status date
Registration date
Jan 2, 2007
Examiner
JUN,WON KYUNG WENDY
Law office
GENERIC WEB UPDATE

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 800: Status 800 means the registration was renewed after acceptable combined Section 8 and Section 9 filings. The mark remains registered for another 10-year term with active federal protection.

Need help with BIOMARIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*

Plus Government fees of $1,300

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Gregory J. Chinlund

Gregory J. Chinlund MARSHALL, GERSTEIN & BORUN LLP6300 WILLIS TOWER233 SOUTH WACKER DRIVECHICAGO, IL 60606-6357

Goods and services

ClassDescriptionStatusFirst use
001[ Assays and diagnostic screening kits composed primarily of reagents for scientific analysis and research for diagnosis of disorders and physiological processes and for measurement of disease markers for scientific purposes ]ACTIVENov 30, 2004
005Pharmaceutical preparations for use in enzyme therapy; pharmaceutical preparations for use in treatment of genetic disorders; [ pharmaceutical preparations for use in burn and wound debridement or cleaning; pharmaceuticals for treatment of inflammation, infectious diseases and cardiovascular diseases; ] assays and diagnostic screening kits composed primarily of reagents for clinical and medical use for analysis and diagnosis of disorders and physiological processes and for measurement of disease markers for medical purposes; carbohydrate inhibiting enzymes for use in disease treatment; [ fungal lytic enzymes for the treatment of fungal infections; ] pharmaceuticals for treatment of lysosomal storage diseases; pharmaceuticals for treatment of mucopolysaccharidoses; pharmaceuticals for treatment of carbohydrate-inhibiting enzyme disorders; [ proteins and enzymes for the production, purification and isolation of biologics for use in the treatment of medical conditions; ] biologics produced by recombinant DNA technology for use in the treatment of pathological medical conditionsACTIVEJun 8, 2005

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 2, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Apr 26, 2016NA89NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED—
Apr 26, 2016RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Apr 26, 201689AGREGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTEDThe USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary.
Apr 26, 2016APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Feb 17, 2016E89RTEAS SECTION 8 & 9 RECEIVED—
Jan 2, 2016REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Nov 30, 2012NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Nov 30, 2012C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Nov 29, 2012APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 2, 2012E815TEAS SECTION 8 & 15 RECEIVED—
Jan 2, 2007R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 17, 2006PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 27, 2006NPUBNOTICE OF PUBLICATION—
Aug 23, 2006PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 18, 2006ALIEASSIGNED TO LIE—
Aug 11, 2006CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 11, 2006XAECEXAMINER'S AMENDMENT ENTERED—
Aug 11, 2006GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 11, 2006CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 31, 2006TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 12, 2006CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 12, 2006TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 2, 2006GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 2, 2006CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 25, 2006DOCKASSIGNED TO EXAMINER—
Oct 25, 2005NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance